{"product_id":"choosing-the-right-blood-pressure-medication-a-complete-patient-guide-to-treating-primary-essential-hypertension","title":"Choosing the Right Blood Pressure Medication: A Complete Patient Guide to Treating Primary (Essential) Hypertension","description":"\u003cp\u003eHypertension (high blood pressure) affects hundreds of millions of people worldwide, and choosing the right medication is one of the most important decisions in modern medicine. This comprehensive guide explains that while there are several excellent first-line drug classes—including ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and thiazide diuretics—the most critical factor for preventing heart attacks, strokes, and death is the \u003cem\u003emagnitude\u003c\/em\u003e of blood pressure reduction rather than the specific drug chosen. The article provides detailed, evidence-based recommendations on when to start with one medication versus two, the benefits of single-pill combinations, and which drug pairings to avoid, all explained in clear language for patients and their families.\u003c\/p\u003e\n\n\u003ch1\u003eChoosing the Right Blood Pressure Medication: A Complete Patient Guide to Treating Primary (Essential) Hypertension\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: Why This Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Understanding Hypertension and Its Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow These Recommendations Were Developed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#initial-therapy\"\u003eInitial Drug Therapy: Where Treatment Begins\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#monotherapy\"\u003eStarting with One Drug (Monotherapy)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#combination-therapy\"\u003eStarting with Two Drugs (Combination Therapy)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#drug-comparison\"\u003eComparing the Main Drug Classes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#thiazide\"\u003eThiazide vs. Thiazide-Like Diuretics: What's the Difference?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Research Shows\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#comorbidities\"\u003ePatients with Other Medical Conditions (Comorbidities)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#avoid-combinations\"\u003eDrug Combinations to Avoid\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#dose-titration\"\u003eDose Titration and Monitoring\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eThe degree of blood pressure lowering matters more than the specific drug class for preventing heart attacks and strokes.\u003c\/li\u003e\n\u003cli\u003eStarting with two medications is recommended when blood pressure is 10-20 mmHg above goal; single-pill combinations improve adherence.\u003c\/li\u003e\n\u003cli\u003eAn ACE inhibitor plus a calcium channel blocker was superior to an ACE inhibitor plus a thiazide diuretic in the ACCOMPLISH trial.\u003c\/li\u003e\n\u003cli\u003eChlorthalidone and indapamide lower systolic pressure 3.6-5.1 mmHg more than hydrochlorothiazide and last longer.\u003c\/li\u003e\n\u003cli\u003eAvoid combining an ACE inhibitor with an ARB, as it causes adverse cardiovascular and kidney events.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: Why This Matters\u003c\/h2\u003e\n\u003cp\u003eHypertension—commonly known as high blood pressure—is a global health crisis. In the United States alone, among nonpregnant adults, treating hypertension is the most common reason for an office visit to a doctor, and it's the most frequent reason for taking a chronic prescription medication.\u003c\/p\u003e\n\u003cp\u003eFor decades, doctors have debated which blood pressure medication is \"best.\" But this article from UpToDate—written by leading experts in hypertension—makes a crucial point: \u003cstrong\u003ethe intensity of treatment (the number of medications and their doses) matters more than the choice of any single drug\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn other words, how aggressively you lower blood pressure is more important than which specific pill you take. That said, certain drug classes do offer special benefits for patients with particular health conditions, and some combinations work better than others. This guide walks you through everything you need to know.\u003c\/p\u003e\n\n\u003ch2 id=\"background\"\u003eBackground: Understanding Hypertension and Its Treatment\u003c\/h2\u003e\n\u003cp\u003eBlood pressure is measured in millimeters of mercury (mmHg) and recorded as two numbers: systolic pressure (the top number, when your heart beats) and diastolic pressure (the bottom number, when your heart rests between beats).\u003c\/p\u003e\n\u003cp\u003eWhen blood pressure stays high over time, it damages blood vessels throughout the body, increasing the risk of heart attack, stroke, kidney failure, and other serious conditions. The goal of treatment is to lower blood pressure enough to prevent these complications.\u003c\/p\u003e\n\u003cp\u003eDecades of research have shown that the degree of blood pressure lowering is the main driver of benefit. For the vast majority of patients, reducing blood pressure by a certain amount produces similar protection against cardiovascular disease regardless of which medication class achieves that reduction.\u003c\/p\u003e\n\u003cp\u003eThe experts from UpToDate note some important nuances: certain drug classes work better than others in patients with specific coexisting conditions (comorbidities), such as heart failure or kidney disease. But for the average patient, the most important thing is simply getting blood pressure down to a healthy level—and keeping it there.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow These Recommendations Were Developed\u003c\/h2\u003e\n\u003cp\u003eThis article is not a single study but rather a comprehensive clinical guideline written by three experts in the field: Johannes FE Mann, MD; John M Flack, MD, MPH, FAHA, FASH, MACP; and section editors George L Bakris, MD, and William B White, MD. The content was reviewed by a deputy editor, John P Forman, MD, MSc.\u003c\/p\u003e\n\u003cp\u003eThe recommendations are based on a thorough review of the medical literature, which was current through April 2023. The article was last updated on May 4, 2023.\u003c\/p\u003e\n\u003cp\u003eThe authors draw on evidence from numerous clinical trials and meta-analyses, including landmark studies such as the \u003cstrong\u003eACCOMPLISH trial\u003c\/strong\u003e (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension), the \u003cstrong\u003eALLHAT trial\u003c\/strong\u003e (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial), and many others. They also align their recommendations with major professional guidelines, including those from the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), and the European Society of Hypertension (ESH).\u003c\/p\u003e\n\u003cp\u003eIt's important to understand that this is a peer-reviewed, evidence-based clinical resource designed to help doctors make informed treatment decisions. This patient version explains those recommendations in plain language while preserving all of the key data.\u003c\/p\u003e\n\n\u003ch2 id=\"initial-therapy\"\u003eInitial Drug Therapy: Where Treatment Begins\u003c\/h2\u003e\n\u003cp\u003eBefore any medication is prescribed, the experts are unanimous: \u003cstrong\u003eevery patient with hypertension should first be prescribed nonpharmacologic (lifestyle) therapy\u003c\/strong\u003e. This includes dietary changes, salt restriction, potassium intake management, weight loss if overweight or obese, and regular exercise. These lifestyle measures are the foundation upon which drug therapy is built.\u003c\/p\u003e\n\u003cp\u003eBut for many patients, lifestyle changes alone aren't enough. The question then becomes: should treatment start with one drug (monotherapy) or two drugs (combination therapy)? The answer depends on how high your blood pressure is above your target goal.\u003c\/p\u003e\n\u003cp\u003eThe UpToDate authors provide a clear framework for making this decision:\u003c\/p\u003e\n\n\u003ch2 id=\"monotherapy\"\u003eStarting with One Drug (Monotherapy)\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMonotherapy is recommended for patients with stage 1 hypertension\u003c\/strong\u003e—defined as a systolic pressure of 130 to 139 mmHg and\/or diastolic pressure of 80 to 89 mmHg—who have been selected for drug therapy. Some experts also start with one drug when the systolic pressure is 140 to 149 mmHg but the diastolic pressure is below 90 mmHg.\u003c\/p\u003e\n\u003cp\u003eMonotherapy is also the preferred starting point for certain patients at higher risk of side effects from blood pressure medications. These higher-risk patients include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePeople adhering to a very low salt intake\u003c\/li\u003e\n  \u003cli\u003ePeople who are underweight or frail\u003c\/li\u003e\n  \u003cli\u003ePeople with a known orthostatic decline in blood pressure (a drop in blood pressure when standing up)\u003c\/li\u003e\n  \u003cli\u003ePeople with a history of multiple drug allergies or intolerances\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRegardless of whether treatment begins with one or two drugs, the initial drug dose should generally be low. There is one notable exception to this rule: \u003cstrong\u003eangiotensin receptor blockers (ARBs)\u003c\/strong\u003e. These medications do not cause severe dose-related side effects, and their maximal antihypertensive effect is moderate in most patients. Therefore, starting with a moderate to high dose of an ARB is reasonable and prevents the need for unnecessary dose titration (gradual adjustment of the dose).\u003c\/p\u003e\n\u003cp\u003eHere's a critically important point for patients: whether you start with one drug or two, \u003cstrong\u003ethe single most important strategy for achieving blood pressure control is avoiding \"therapeutic inertia.\"\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhat is therapeutic inertia? It's the failure of a doctor to initiate or adjust\/intensify prescribed drug therapy even when your blood pressure is recognized as uncontrolled. This is a bigger problem than you might think.\u003c\/p\u003e\n\u003cp\u003eThe data are striking: a nationally representative survey of ambulatory primary care practices in the United States found that when blood pressure was above 140\/90 mmHg, \u003cstrong\u003etreatment was intensified with a prescription of a new drug at only 17 percent of office visits\u003c\/strong\u003e. In other words, more than 80 percent of the time, when patients came in with high blood pressure, no medication change was made.\u003c\/p\u003e\n\u003cp\u003eThis problem of therapeutic inertia actually has a greater impact on inadequate hypertension control than patients failing to take their prescribed medications. So if your blood pressure isn't controlled, don't be afraid to speak up and ask your doctor whether your treatment should be adjusted.\u003c\/p\u003e\n\n\u003ch3\u003eWhich Drug for Monotherapy?\u003c\/h3\u003e\n\u003cp\u003eThe three primary options for antihypertensive drug therapy in most patients are:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eAn ACE inhibitor (angiotensin-converting enzyme inhibitor) or ARB (angiotensin receptor blocker)\u003c\/li\u003e\n  \u003cli\u003eA calcium channel blocker\u003c\/li\u003e\n  \u003cli\u003eA thiazide diuretic (preferably a thiazide-like diuretic)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eIf there are no compelling reasons to select a specific drug class, the UpToDate experts suggest treating with \u003cstrong\u003ean ACE inhibitor (or ARB) or a dihydropyridine calcium channel blocker\u003c\/strong\u003e, rather than a thiazide diuretic.\u003c\/p\u003e\n\u003cp\u003eWhen used as monotherapy, these four drug classes produce similar benefits on cardiovascular endpoints (heart attacks, strokes, and death from cardiovascular causes). However, the combination of an ACE inhibitor and a dihydropyridine calcium channel blocker may provide \u003cstrong\u003esuperior protection against cardiovascular events\u003c\/strong\u003e compared with a combination of a thiazide diuretic with the same ACE inhibitor.\u003c\/p\u003e\n\u003cp\u003eThere's a practical reason for this recommendation. Since the majority of patients who begin treatment with monotherapy will ultimately require additional drugs to control their blood pressure, starting with a medicine that is part of the optimal two-drug combination is a simpler strategy than starting with, for example, a thiazide diuretic and then—when a second drug becomes necessary—switching medications entirely.\u003c\/p\u003e\n\u003cp\u003eThe data supporting this approach come from the ACCOMPLISH trial, which will be discussed in more detail below.\u003c\/p\u003e\n\u003cp\u003eNevertheless, a thiazide diuretic remains a reasonable alternative for monotherapy, and it may actually be preferred over an ACE inhibitor, ARB, or dihydropyridine calcium channel blocker in specific situations:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients with edema (fluid retention\/swelling)\u003c\/li\u003e\n  \u003cli\u003ePatients with osteoporosis (thiazides have beneficial effects on bone metabolism)\u003c\/li\u003e\n  \u003cli\u003ePatients with calcium nephrolithiasis with hypercalciuria (calcium-containing kidney stones caused by excess calcium in the urine)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen a thiazide diuretic is used, the experts recommend choosing a \u003cstrong\u003ethiazide-like diuretic (chlorthalidone or indapamide)\u003c\/strong\u003e rather than hydrochlorothiazide. The evidence for this preference is covered in detail in the section on diuretics below.\u003c\/p\u003e\n\n\u003ch3\u003eWhy Beta Blockers Are Not First-Line\u003c\/h3\u003e\n\u003cp\u003eIn the absence of a compelling indication (such as a recent heart attack), the UpToDate authors and others recommend that \u003cstrong\u003ebeta blockers NOT be used as first-line therapy\u003c\/strong\u003e, particularly in patients over age 60.\u003c\/p\u003e\n\u003cp\u003eThe evidence shows that compared with other antihypertensive drugs, beta blockers are associated with:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eInferior protection against stroke risk\u003c\/li\u003e\n  \u003cli\u003eInferior protection against all-cause mortality\u003c\/li\u003e\n  \u003cli\u003eImpaired glucose tolerance\u003c\/li\u003e\n  \u003cli\u003eAn increased risk of new-onset diabetes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese disadvantages are primarily seen in patients over age 60. There are exceptions: vasodilating beta blockers such as carvedilol and nebivolol do not appear to have the same negative metabolic effects. But for most patients with uncomplicated hypertension, beta blockers should not be the first choice.\u003c\/p\u003e\n\n\u003ch2 id=\"combination-therapy\"\u003eStarting with Two Drugs (Combination Therapy)\u003c\/h2\u003e\n\u003cp\u003eFor patients whose blood pressure is further from their goal, starting with two medications makes sense. The UpToDate guidance is clear:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\"In general, patients with a systolic pressure 10 to 20 mmHg above goal and\/or a diastolic pressure 10 mmHg above goal should have antihypertensive drug therapy initiated with low to moderate doses of two agents with complementary mechanisms of action.\"\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome experts begin with two agents in patients with stage 2 hypertension (systolic pressure ≥140 mmHg and\/or diastolic ≥90 mmHg), while others prefer to start two drugs when systolic pressure is ≥150 mmHg and\/or diastolic is ≥90 mmHg.\u003c\/p\u003e\n\u003cp\u003eWhy start with two drugs instead of one?\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eCombination therapy lowers blood pressure more than monotherapy\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIt increases the likelihood that target blood pressure will be achieved in a reasonable time period\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIt allows attainment of goal blood pressure with lower doses of each medication, which reduces the risk of dose-related side effects\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis approach is consistent with guidelines from the ACC\/AHA and the ESC\/ESH.\u003c\/p\u003e\n\n\u003ch3\u003eThe Single-Pill Advantage\u003c\/h3\u003e\n\u003cp\u003eWhen starting treatment with two agents, the experts \u003cstrong\u003estrongly suggest using a single-pill combination\u003c\/strong\u003e—that is, one pill containing both medications—rather than taking two separate pills (known as \"free equivalents\").\u003c\/p\u003e\n\u003cp\u003eThe evidence shows that single-pill combinations lead to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eGreater blood pressure reduction\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIncreased attainment of blood pressure goal\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBetter medication adherence\u003c\/strong\u003e (patients are more likely to take one pill than two)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eObservational data also suggest that single-pill combination therapy reduces the risk of cardiovascular disease and mortality compared with free equivalents.\u003c\/p\u003e\n\u003ch3\u003eWhen Separate Pills Make More Sense\u003c\/h3\u003e\n\u003cp\u003eThere are situations where starting with free equivalents (separate pills) is the better choice:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatients with a history of multiple drug allergies or intolerances:\u003c\/strong\u003e Starting with one drug and then adding a second agent several weeks later makes it less complicated for the clinician to identify the culprit drug if a side effect occurs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplex cases of hypertension:\u003c\/strong\u003e Free equivalents are easier to titrate when frequent dose adjustment is needed. This applies to patients with renovascular hypertension (high blood pressure caused by narrowing of the kidney arteries) or other secondary forms of hypertension, as well as those with target organ damage such as heart failure or kidney function impairment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn these situations, once blood pressure is controlled and the patient is tolerating therapy, the free equivalents can often be switched to a single-pill combination for convenience and adherence.\u003c\/p\u003e\n\u003cp\u003eIt's also worth noting that single-pill combinations are not always perfect for everyone:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThey are often more expensive\u003c\/li\u003e\n  \u003cli\u003eThey may not be covered by prescription drug insurance\u003c\/li\u003e\n  \u003cli\u003eTheir availability varies by region\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhich Two-Drug Combination is Preferred?\u003c\/h3\u003e\n\u003cp\u003eWhen two drugs are used, they should be from different antihypertensive drug classes. In most patients, the drugs should be selected from among the \u003cstrong\u003ethree preferred classes\u003c\/strong\u003e:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eACE inhibitors (or ARBs)\u003c\/li\u003e\n  \u003cli\u003eCalcium channel blockers\u003c\/li\u003e\n  \u003cli\u003eThiazide diuretics (ideally a thiazide-like rather than a thiazide-type diuretic)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eFor patients without an indication for a non-preferred agent, the UpToDate experts suggest treating with \u003cstrong\u003ethe combination of an ACE inhibitor (or ARB) and a calcium channel blocker, preferably a dihydropyridine calcium blocker\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis recommendation flows from the ACCOMPLISH trial, which we'll examine in the Key Findings section below.\u003c\/p\u003e\n\u003cp\u003eThe combination of an ACE inhibitor (or ARB) with a thiazide diuretic is a reasonable alternative, particularly for patients who have conditions that can benefit from a thiazide diuretic (such as edema, osteoporosis, or calcium kidney stones with hypercalciuria). However, a few important notes apply:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThiazide-like diuretics (chlorthalidone, indapamide) are preferred over thiazide-type diuretics (hydrochlorothiazide)\u003c\/li\u003e\n  \u003cli\u003eThere are only \u003cstrong\u003etwo single-pill combinations available\u003c\/strong\u003e that combine an ACE inhibitor (or ARB) with a thiazide-like diuretic: perindopril-indapamide and azilsartan-chlorthalidone\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTreating with a calcium channel blocker and a thiazide diuretic is also a reasonable option, but there are \u003cstrong\u003eno single-pill combinations\u003c\/strong\u003e of these two classes currently available.\u003c\/p\u003e\n\n\u003ch2 id=\"drug-comparison\"\u003eComparing the Main Drug Classes\u003c\/h2\u003e\n\u003cp\u003eLet's take a closer look at each major drug class, how they work, and what patients should know.\u003c\/p\u003e\n\n\u003ch3\u003eACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)\u003c\/h3\u003e\n\u003cp\u003eThese drugs work by blocking the conversion of angiotensin I to angiotensin II, a hormone that narrows blood vessels. By reducing angiotensin II levels, ACE inhibitors allow blood vessels to relax and widen, lowering blood pressure.\u003c\/p\u003e\n\u003cp\u003eCommon examples include lisinopril, enalapril, ramipril, and perindopril.\u003c\/p\u003e\n\u003cp\u003eACE inhibitors are especially valuable in patients with:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHeart failure\u003c\/li\u003e\n  \u003cli\u003eDiabetes with kidney disease (albuminuria)\u003c\/li\u003e\n  \u003cli\u003eAfter a heart attack (myocardial infarction)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eARBs (Angiotensin Receptor Blockers)\u003c\/h3\u003e\n\u003cp\u003eARBs work similarly to ACE inhibitors but block the action of angiotensin II at a different point in the pathway—at the receptor level. They have a similar effect on blood pressure but generally cause less cough, a common side effect of ACE inhibitors.\u003c\/p\u003e\n\u003cp\u003eCommon examples include losartan, valsartan, candesartan, and azilsartan.\u003c\/p\u003e\n\u003cp\u003eAs noted earlier, ARBs are unique in that they do not cause severe dose-related side effects, so starting at a moderate to high dose is reasonable.\u003c\/p\u003e\n\n\u003ch3\u003eCalcium Channel Blockers\u003c\/h3\u003e\n\u003cp\u003eThese drugs prevent calcium from entering the muscle cells of the heart and blood vessels, causing the blood vessels to relax. The dihydropyridine calcium channel blockers (such as amlodipine, nifedipine, and felodipine) primarily affect blood vessels, while non-dihydropyridine calcium channel blockers (such as verapamil and diltiazem) also affect the heart.\u003c\/p\u003e\n\u003cp\u003eCalcium channel blockers are especially useful in elderly patients, patients with isolated systolic hypertension, and patients of African ancestry.\u003c\/p\u003e\n\n\u003ch3\u003eThiazide Diuretics\u003c\/h3\u003e\n\u003cp\u003eThese \"water pills\" work by causing the kidneys to remove excess sodium and water from the body, which reduces blood volume and lowers blood pressure. They also cause blood vessel relaxation.\u003c\/p\u003e\n\u003cp\u003eThere are two main types:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThiazide-type diuretics:\u003c\/strong\u003e hydrochlorothiazide\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThiazide-like diuretics:\u003c\/strong\u003e chlorthalidone, indapamide\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis distinction matters a great deal, as discussed below in the dedicated section.\u003c\/p\u003e\n\n\u003ch2 id=\"thiazide\"\u003eThiazide vs. Thiazide-Like Diuretics: What's the Difference?\u003c\/h2\u003e\n\u003cp\u003eThis is one of the most detailed and technically specific sections of the original article, and it deserves careful attention because it affects millions of prescriptions.\u003c\/p\u003e\n\u003cp\u003eThe UpToDate authors are unequivocal: \u003cstrong\u003ewhen a thiazide diuretic is used, chlorthalidone or indapamide (thiazide-like diuretics) are significantly more potent antihypertensive agents than hydrochlorothiazide (a thiazide-type diuretic) at similar dose levels.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eThe Meta-Analysis Evidence\u003c\/h3\u003e\n\u003cp\u003eA meta-analysis of 14 trials compared the blood pressure reduction achieved with one of three dose levels of hydrochlorothiazide (low, intermediate, high) against a similar dose of one of the thiazide-like diuretics. The results were clear:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eChlorthalidone lowered systolic pressure by 3.6 mmHg more than hydrochlorothiazide\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eIndapamide lowered systolic pressure by 5.1 mmHg more than hydrochlorothiazide\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese differences are clinically meaningful. A 3.6 to 5.1 mmHg reduction in systolic blood pressure might not sound like much, but at the population level, even small reductions in blood pressure translate into significant reductions in heart attacks, strokes, and deaths.\u003c\/p\u003e\n\n\u003ch3\u003eThe Duration of Action Difference\u003c\/h3\u003e\n\u003cp\u003ePerhaps even more important than potency is the difference in duration of action:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChlorthalidone and indapamide:\u003c\/strong\u003e 24 or more hours of blood pressure-lowering effect\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHydrochlorothiazide:\u003c\/strong\u003e only 6 to 12 hours\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis difference may not affect office blood pressure readings if the medication is taken in the morning (because the effect is measured during the day). But the longer-acting drugs produce a greater fall in \u003cstrong\u003enighttime blood pressure\u003c\/strong\u003e, which is important for overall cardiovascular protection.\u003c\/p\u003e\n\u003cp\u003eIn one small trial, nighttime blood pressure decreased by \u003cstrong\u003e13.5 mmHg\u003c\/strong\u003e with 25 mg\/day of chlorthalidone, compared with only \u003cstrong\u003e6.4 mmHg\u003c\/strong\u003e with 50 mg\/day of hydrochlorothiazide. That's more than double the nighttime blood pressure reduction with the thiazide-like drug at half the dose.\u003c\/p\u003e\n\n\u003ch3\u003eThe Veteran's Affairs Trial: A Head-to-Head Comparison\u003c\/h3\u003e\n\u003cp\u003eThe two drugs were directly compared in a large trial involving \u003cstrong\u003e13,523 older male veterans\u003c\/strong\u003e (mean age 72 years) who had uncontrolled hypertension (mean systolic pressure 139 mmHg) despite taking hydrochlorothiazide 25 mg daily. Of these patients, 87 percent were also taking other antihypertensive agents, while 13 percent were taking hydrochlorothiazide alone.\u003c\/p\u003e\n\u003cp\u003ePatients were randomly assigned to either continue hydrochlorothiazide or switch to 12.5 mg of chlorthalidone. The results after 2.4 years of follow-up:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRates of \u003cstrong\u003eall-cause mortality, stroke, myocardial infarction, and hospitalization for heart failure were the same\u003c\/strong\u003e in each group\u003c\/li\u003e\n  \u003cli\u003eBlood pressure was also similar between the groups—and importantly, remained uncontrolled throughout the trial in both groups\u003c\/li\u003e\n  \u003cli\u003eLow potassium (serum potassium ≤3 mEq\/L) occurred in \u003cstrong\u003e5 percent\u003c\/strong\u003e of those taking chlorthalidone and \u003cstrong\u003e3.6 percent\u003c\/strong\u003e of those taking hydrochlorothiazide\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAt first glance, this might seem to argue that the two drugs are equivalent. But the UpToDate authors point out several serious limitations with this trial that should make patients and doctors cautious about drawing that conclusion.\u003c\/p\u003e\n\n\u003ch3\u003eWhy the Veteran's Trial Results Might Be Misleading\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eThe primary problem: the wrong dose was used.\u003c\/strong\u003e When a patient has uncontrolled blood pressure despite taking 25 mg of hydrochlorothiazide, the standard approach would be to switch the patient to 25 mg of chlorthalidone—not 12.5 mg. The 12.5 mg dose is half the dose that was used in major cardiovascular outcome trials, such as ALLHAT.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHigh crossover rates:\u003c\/strong\u003e More than 15 percent of patients assigned to chlorthalidone switched back to hydrochlorothiazide during the trial, whereas only 4 percent switched from hydrochlorothiazide to chlorthalidone. This asymmetry could have biased the results toward showing no difference (toward the null).\u003c\/p\u003e\n\u003cp\u003eWhy did so many patients switch? The authors speculate that it may be because chlorthalidone tablets are not available in a 12.5 mg pill and are typically not scored (not grooved for splitting), forcing patients to split their tablets—a cumbersome and potentially imprecise process.\u003c\/p\u003e\n\n\u003ch3\u003eThe Bigger Picture: What Other Studies Show\u003c\/h3\u003e\n\u003cp\u003eOther studies, including several network meta-analyses, have concluded that \u003cstrong\u003ecardiovascular outcomes were superior with chlorthalidone compared with hydrochlorothiazide\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eBy contrast, some retrospective observational studies suggest that the two drugs lead to similar rates of cardiovascular events but that chlorthalidone increases the risk of adverse metabolic effects (such as hypokalemia—low potassium).\u003c\/p\u003e\n\u003cp\u003eHowever, there's an important mitigation strategy: the metabolic derangements associated with chlorthalidone can be attenuated, at least in part, by pairing it with an ACE inhibitor or an ARB. This is one reason why the combination of an ACE inhibitor plus a thiazide-like diuretic is a commonly used and effective treatment strategy.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Research Shows\u003c\/h2\u003e\n\u003cp\u003eLet's consolidate the major findings from the evidence base referenced in this article:\u003c\/p\u003e\n\n\u003ch3\u003e1. The ACCOMPLISH Trial: ACE Inhibitor + Calcium Channel Blocker Wins\u003c\/h3\u003e\n\u003cp\u003eThe ACCOMPLISH trial (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) provides critical evidence for choosing between two-drug combinations.\u003c\/p\u003e\n\u003cp\u003eThe trial compared two combinations in patients with systolic hypertension:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAn ACE inhibitor (benazepril) combined with a dihydropyridine calcium channel blocker (amlodipine)\u003c\/li\u003e\n  \u003cli\u003eThe same ACE inhibitor (benazepril) combined with a thiazide diuretic (hydrochlorothiazide)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe result was clear: \u003cstrong\u003ethe combination of an ACE inhibitor and a dihydropyridine calcium channel blocker provided superior protection against cardiovascular events\u003c\/strong\u003e compared with the combination of the ACE inhibitor and the thiazide diuretic.\u003c\/p\u003e\n\u003cp\u003eThis is why the UpToDate authors recommend the ACE inhibitor (or ARB) + calcium channel blocker as the preferred initial combination therapy for most patients.\u003c\/p\u003e\n\n\u003ch3\u003e2. Therapeutic Inertia is a Major Problem\u003c\/h3\u003e\n\u003cp\u003eAs highlighted earlier, a nationally representative survey of ambulatory primary care practices found that when blood pressure was above 140\/90 mmHg, treatment was intensified with a new drug prescription at \u003cstrong\u003eonly 17 percent of office visits\u003c\/strong\u003e. This means 83 percent of visits with uncontrolled hypertension resulted in no treatment change.\u003c\/p\u003e\n\u003cp\u003eThis fundamental finding underscores the importance of patients being active participants in their own care. If your blood pressure is consistently above goal, don't assume that \"wait and see\" is the right approach—ask your doctor about adjusting your treatment.\u003c\/p\u003e\n\n\u003ch3\u003e3. Beta Blockers Are Weaker at Preventing Stroke\u003c\/h3\u003e\n\u003cp\u003eCompared with other antihypertensive drugs, beta blockers appear to be associated with \u003cstrong\u003einferior protection against stroke risk and all-cause mortality\u003c\/strong\u003e. These disadvantages are primarily seen in patients over age 60.\u003c\/p\u003e\n\u003cp\u003eBeta blockers are also associated with impaired glucose tolerance and an increased risk of new-onset diabetes. The exceptions are vasodilating beta blockers such as carvedilol and nebivolol, which do not appear to carry the same metabolic risks.\u003c\/p\u003e\n\n\u003ch3\u003e4. Chlorthalidone and Indapamide Are More Potent Than Hydrochlorothiazide\u003c\/h3\u003e\n\u003cp\u003eFrom the meta-analysis of 14 trials:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eChlorthalidone lowers systolic pressure by an additional 3.6 mmHg\u003c\/li\u003e\n  \u003cli\u003eIndapamide lowers systolic pressure by an additional 5.1 mmHg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBoth thiazide-like diuretics also last much longer in the body (24+ hours vs. 6-12 hours for hydrochlorothiazide), providing better nighttime blood pressure control.\u003c\/p\u003e\n\n\u003ch3\u003e5. Single-Pill Combinations Improve Adherence\u003c\/h3\u003e\n\u003cp\u003eMultiple studies confirm that single-pill combinations (both drugs in one pill) lead to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGreater blood pressure reduction\u003c\/li\u003e\n  \u003cli\u003eIncreased attainment of blood pressure goal\u003c\/li\u003e\n  \u003cli\u003eBetter medication adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eObservational data suggest that single-pill combination therapy reduces the risk of cardiovascular disease and mortality compared with taking the same drugs as separate pills.\u003c\/p\u003e\n\n\u003ch2 id=\"comorbidities\"\u003ePatients with Other Medical Conditions (Comorbidities)\u003c\/h2\u003e\n\u003cp\u003eSome patients have compelling reasons to use a specific drug class based on their other medical conditions. The original article references a detailed table that guides these decisions. Here are the key situations where specific drug classes are preferred:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeart failure with preserved ejection fraction:\u003c\/strong\u003e Mineralocorticoid receptor antagonists (spironolactone, eplerenone) have special benefits\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAfter a myocardial infarction (heart attack):\u003c\/strong\u003e Beta blockers are recommended because they reduce the risk of future cardiovascular events\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes with kidney disease (albuminuria):\u003c\/strong\u003e ACE inhibitors or ARBs are preferred because they protect kidney function\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEdema (fluid retention):\u003c\/strong\u003e Thiazide diuretics help reduce swelling\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOsteoporosis:\u003c\/strong\u003e Thiazide diuretics have beneficial effects on bone metabolism by reducing calcium loss in urine\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrent calcium kidney stones (calcium nephrolithiasis with hypercalciuria):\u003c\/strong\u003e Thiazide diuretics reduce calcium excretion in urine, helping prevent stone formation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf you have any of these conditions, your doctor may choose a medication that is different from what would be prescribed for a patient without those conditions. This is called a \"compelling indication.\"\u003c\/p\u003e\n\n\u003ch2 id=\"avoid-combinations\"\u003eDrug Combinations to Avoid\u003c\/h2\u003e\n\u003cp\u003eNot all drug combinations are safe or effective. In fact, one combination in particular is explicitly warned against:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePatients should NOT simultaneously be prescribed both an ACE inhibitor and an ARB.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCombining these two drugs is associated with \u003cstrong\u003eadverse cardiovascular and kidney events\u003c\/strong\u003e. Despite both drugs targeting the same blood pressure pathway (the renin-angiotensin system), combining them does not add meaningful benefit but does add harm.\u003c\/p\u003e\n\u003cp\u003eThis warning is consistent across multiple guidelines and is reinforced in several specific clinical contexts, including diabetes and chronic kidney disease. If you are currently taking both an ACE inhibitor and an ARB, you should discuss this with your doctor—there may be a safer alternative.\u003c\/p\u003e\n\n\u003ch2 id=\"dose-titration\"\u003eDose Titration and Monitoring\u003c\/h2\u003e\n\u003cp\u003eThe original article references detailed guidance on dose titration and monitoring, which is discussed in other sections of the UpToDate resource. The key principles are:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eStart at a low dose\u003c\/li\u003e\n  \u003cli\u003eAdjust (titrate) the dose based on blood pressure response and tolerance\u003c\/li\u003e\n  \u003cli\u003eAdd a second medication if blood pressure remains uncontrolled on the maximum tolerated dose of the first medication\u003c\/li\u003e\n  \u003cli\u003eMonitor regularly to confirm blood pressure control and check for side effects\u003c\/li\u003e\n  \u003cli\u003eCheck laboratory values as appropriate (potassium, kidney function, etc.) depending on which medications are used\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe most important message is this: \u003cstrong\u003eavoid therapeutic inertia\u003c\/strong\u003e. If your blood pressure isn't at goal, your treatment should be adjusted—whether that means increasing the dose, adding a new medication, or switching to a different class.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThis comprehensive review has several practical implications for patients living with hypertension.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the most important thing is lowering your blood pressure—period.\u003c\/strong\u003e The specific medication matters less than the degree of blood pressure reduction. So don't get too caught up in which drug you're taking; focus on whether your blood pressure is actually at goal.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, if your blood pressure is significantly above goal (more than 10-20 mmHg systolic above target), two medications are better than one.\u003c\/strong\u003e Starting with combination therapy gets you to goal faster and with fewer side effects than a single medication at a high dose.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, ask about single-pill combinations.\u003c\/strong\u003e If you need two medications, taking one pill that contains both drugs dramatically improves adherence. This matters because observational data show that single-pill combinations reduce the risk of cardiovascular disease and death compared with taking two separate pills.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, if you need a diuretic, ask if a thiazide-like diuretic (chlorthalidone or indapamide) might be better for you than hydrochlorothiazide.\u003c\/strong\u003e The evidence shows these drugs are more potent and last longer. However, they also carry a slightly higher risk of low potassium (hypokalemia), but this can be managed by combining with an ACE inhibitor or ARB and by monitoring blood tests.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFifth, if you're over 60 and taking a beta blocker as your only blood pressure medication, ask your doctor whether it's the best choice for you.\u003c\/strong\u003e Beta blockers are clearly beneficial after a heart attack and in heart failure, but for uncomplicated hypertension in older adults, other drug classes provide better stroke protection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSixth, never take both an ACE inhibitor and an ARB together.\u003c\/strong\u003e If you are, talk to your doctor about switching.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSeventh, be your own advocate.\u003c\/strong\u003e The fact that treatment was intensified at only 17 percent of office visits when blood pressure was above 140\/90 is a wake-up call. If your blood pressure is consistently high, speak up. Ask your healthcare provider why your treatment hasn't been adjusted and what the plan is to get you to goal.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Research\u003c\/h2\u003e\n\u003cp\u003eWhile the evidence base for antihypertensive therapy is extraordinarily robust, the authors acknowledge several limitations in the specific studies discussed:\u003c\/p\u003e\n\n\u003ch3\u003eLimitations of Chlorthalidone vs. Hydrochlorothiazide Research\u003c\/h3\u003e\n\u003cp\u003eThe Veteran's Affairs trial that found no difference between chlorthalidone and hydrochlorothiazide was hampered by significant design problems:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe chlorthalidone dose used (12.5 mg) was half the clinically recommended dose of 25 mg\u003c\/li\u003e\n  \u003cli\u003eMore than 15 percent of patients in the chlorthalidone group switched back to hydrochlorothiazide, while only 4 percent switched in the opposite direction—a bias that would tend to obscure any real difference\u003c\/li\u003e\n  \u003cli\u003eBlood pressure remained uncontrolled in both groups throughout the trial, suggesting that the overall treatment intensity was inadequate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdditionally, some retrospective observational studies suggest that chlorthalidone may increase metabolic side effects (including low potassium and possibly higher blood sugar) compared to hydrochlorothiazide, though the authors note these effects can be mitigated by combining chlorthalidone with an ACE inhibitor or ARB.\u003c\/p\u003e\n\n\u003ch3\u003eLimitations of Combination Therapy Research\u003c\/h3\u003e\n\u003cp\u003eThe experience with \"polypill\" strategies—initiating treatment with more than two antihypertensive agents at once—is limited. While some trials have examined this approach, the evidence base is not yet strong enough to recommend it routinely.\u003c\/p\u003e\n\n\u003ch3\u003eGeneral Limitations of Clinical Guidelines\u003c\/h3\u003e\n\u003cp\u003eClinical guidelines are based on population-level data, and individual responses to medications vary widely. What works best for one patient may not work for another. Race, age, genetics, diet, and coexisting conditions all influence how a person responds to antihypertensive therapy. These guidelines are starting points, not rigid rules.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on this comprehensive review, here are actionable recommendations for patients with hypertension:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't skip lifestyle changes.\u003c\/strong\u003e Every hypertensive patient should be prescribed nonpharmacologic therapy: reduce salt intake, eat a healthy diet (such as the DASH diet), maintain adequate potassium intake (unless contraindicated), achieve and maintain a healthy weight, and exercise regularly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your numbers and your goal.\u003c\/strong\u003e Understand your target blood pressure and whether you're above it. Ask your doctor what your specific goal is, as it may vary based on age and other conditions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf your blood pressure is 10-20 mmHg above goal, ask about starting with two medications.\u003c\/strong\u003e Combination therapy gets you to goal faster and with fewer side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk for a single-pill combination if you need two medications.\u003c\/strong\u003e It improves adherence, and evidence shows it reduces cardiovascular risk more than separate pills.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you need a diuretic, ask about chlorthalidone or indapamide.\u003c\/strong\u003e These thiazide-like diuretics are more potent and last longer than hydrochlorothiazide, though you may need additional potassium monitoring.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you're over age 60 with uncomplicated hypertension, ask why you're taking a beta blocker.\u003c\/strong\u003e Other classes provide better stroke protection. If you have had a heart attack or have heart failure, a beta blocker may be exactly right for you—but that's a different situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNever take an ACE inhibitor and an ARB together.\u003c\/strong\u003e This combination increases the risk of kidney and cardiovascular harm.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdvocate for treatment adjustment when needed.\u003c\/strong\u003e If your blood pressure remains above goal at multiple visits, ask for a change. Remember, more than 80 percent of visits with uncontrolled hypertension result in no treatment change—but that doesn't mean it's okay. You have the right to ask for better blood pressure control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake your medications as prescribed.\u003c\/strong\u003e Adherence is one of the most powerful predictors of blood pressure control. If you're having trouble affording medications or remembering to take them, talk to your doctor or pharmacist—there are usually solutions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor at home.\u003c\/strong\u003e Home blood pressure monitoring provides valuable information that office readings can miss, particularly nighttime blood pressure. Consider using a validated home blood pressure monitor and bringing your readings to appointments.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eRemember that hypertension is a chronic condition that requires ongoing management. It's a marathon, not a sprint. Find a healthcare provider who takes your blood pressure seriously, educate yourself, and take an active role in your treatment. The evidence is clear: achieving blood pressure control dramatically reduces the risk of heart attack, stroke, kidney failure, and premature death.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the most important factor in choosing a blood pressure medication?\u003c\/h3\u003e\n\u003cp\u003eThe most important factor is how much your blood pressure is lowered, not which specific drug you take. Lowering blood pressure significantly reduces the risk of heart attack, stroke, and death. For most patients, different drug classes provide similar protection if they achieve the same blood pressure reduction.\u003c\/p\u003e\n\u003ch3\u003eShould I start with one blood pressure pill or two?\u003c\/h3\u003e\n\u003cp\u003eIt depends on how high your blood pressure is above your goal. If your systolic pressure is 10 to 20 mmHg above goal or your diastolic pressure is 10 mmHg above goal, starting with two medications is recommended. Two drugs lower blood pressure more effectively and often with fewer side effects than one high-dose pill.\u003c\/p\u003e\n\u003ch3\u003eWhat is a single-pill combination and why is it recommended?\u003c\/h3\u003e\n\u003cp\u003eA single-pill combination contains two blood pressure medications in one tablet. Taking one pill improves medication adherence and leads to better blood pressure control. Observational data suggest it may also reduce the risk of cardiovascular disease and death compared with taking the same drugs as separate pills.\u003c\/p\u003e\n\u003ch3\u003eWhich two-drug combination is preferred for most patients?\u003c\/h3\u003e\n\u003cp\u003eFor most patients without a specific reason to choose differently, the preferred combination is an ACE inhibitor (or ARB) plus a calcium channel blocker. This was shown in the ACCOMPLISH trial to provide superior protection against cardiovascular events compared with an ACE inhibitor plus a thiazide diuretic.\u003c\/p\u003e\n\u003ch3\u003eWhy should beta blockers not be my first blood pressure medicine if I am over 60?\u003c\/h3\u003e\n\u003cp\u003eFor patients over 60 with uncomplicated hypertension, beta blockers are associated with inferior stroke protection and all-cause mortality compared with other drug classes. They also impair glucose tolerance and increase the risk of new-onset diabetes. Exceptions include vasodilating beta blockers like carvedilol and nebivolol.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Choice of drug therapy in primary (essential) hypertension - UpToDate\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Johannes FE Mann, MD; John M Flack, MD, MPH, FAHA, FASH, MACP\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSection Editors:\u003c\/strong\u003e George L Bakris, MD; William B White, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeputy Editor:\u003c\/strong\u003e John P Forman, MD, MSc\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLiterature Review Current Through:\u003c\/strong\u003e April 2023\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTopic Last Updated:\u003c\/strong\u003e May 4, 2023\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSource:\u003c\/strong\u003e UpToDate, a peer-reviewed clinical resource widely used by healthcare professionals worldwide.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research and clinical guidelines. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider before making any changes to your medications.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458559852700,"sku":null,"price":0.0,"currency_code":"RUB","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ru\/products\/choosing-the-right-blood-pressure-medication-a-complete-patient-guide-to-treating-primary-essential-hypertension","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}